Skip to main content
SpringerLink
Log in

TiA1 in advanced-stage classical Hodgkin’s lymphoma: no prognostic impact for positive tumour cells or number of cytotoxic cells

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

No reliable marker still exists for predicting those patients with Hodgkin’s lymphoma (HL) who may experience a fatal outcome. Among the factors tested in the literature, it has been suggested that the number of activated cytotoxic T cells may represent a prognostic marker in HL. In 244 samples from patients with stage-IIIB/IV HL issued from the GELA H89 trial, we have analysed TiA1 expression on Reed Sternberg (RS) cells as well as the percentage of positive reactive lymphocytes. There were 34 cases (13.7%) that showed TiA1 expression on tumour cells; whereas, in 32 cases (13.1%), TiA1-positive reactive lymphocytes represented more than 30% of the reactive lymphocytes. LMP-1 was found co-expressed with TiA1 in 10 of the 22 positive cases tested. Our study confirms that a subset of classical HL expresses cytotoxic proteins, with occasional co-expression of CD20. In stage-IIIB/IV disease, neither TiA1 expression by RS cells nor a high percentage of TiA1-positive reactive lymphocytes have a prognostic impact on outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Anderson P, Nagler-Anderson C, O’Brien C et al (1990) A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes. J Immunol 144:574–582

    CAS  PubMed  Google Scholar 

  2. Felgar RE, Macon WR, Kinney MC et al (1997) TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol 150:1893–1900

    CAS  PubMed  Google Scholar 

  3. Fermé C, Sebban C, Hennequin C et al (2000) Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin’s disease: results of the Groupe d’étude des Lymphomes de l’Adulte H89 trial. Blood 95:2246–2252

    Google Scholar 

  4. Kanavaros P, Vlychou M, Stefanaki K et al (1999) Cytotoxic protein expression in non-Hodgkin’s lymphomas and Hodgkin’s disease. Anticancer Res 19:1209–1216

    CAS  PubMed  Google Scholar 

  5. Krenacs L, Wellmann A, Sorbara L et al (1997) Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin’s disease: evidence for distinct cellular origin. Blood 89:980–989

    CAS  PubMed  Google Scholar 

  6. Mantel N (1966) Evaluation for survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163

    CAS  PubMed  Google Scholar 

  7. Muschen M, Rajewsky K, Brauninger A et al (2000) Rare occurrence of classical Hodgkin’s disease as a T cell lymphoma. J Exp Med 191:387–394

    PubMed  Google Scholar 

  8. Oudejans JJ, Jiwa NM, Kummer JA et al (1997) Activated cytotoxic T cells as prognostic marker in Hodgkin’s disease. Blood 89:1376–1382

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank J. Diebold for his helpful comments.

Author information

Authors and Affiliations

  1. Service Central d’Anatomie et de Cytologie Pathologiques, Hotel-Dieu 1, Place du Parvis Notre Dame, 75181 , Paris Cedex 04, France

    Sophie Camilleri-Broët, Serge Bain, Béatrice Marmey & Josée Audouin

  2. Institut Gustave Roussy, Villejuif, France

    Christophe Fermé

  3. Centre Hospitalier Lyon-Sud, Lyon, France

    Françoise Berger

  4. Hôpital Henri Mondor, Créteil, France

    Eric Lepage & Philippe Gaulard

  5. Hôpital Saint Louis, Paris, France

    Josette Brière

Authors
  1. Sophie Camilleri-Broët
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christophe Fermé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Françoise Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eric Lepage
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Serge Bain
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Josette Brière
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Béatrice Marmey
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Philippe Gaulard
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Josée Audouin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sophie Camilleri-Broët.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Camilleri-Broët, S., Fermé, C., Berger, F. et al. TiA1 in advanced-stage classical Hodgkin’s lymphoma: no prognostic impact for positive tumour cells or number of cytotoxic cells. Virchows Arch 445, 344–346 (2004). https://doi.org/10.1007/s00428-004-1057-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-004-1057-6

Keywords

Search

Navigation